Possible near-term catalysts?FDA fast-track requires treating (and meeting endpoints) for 20-25 patients and I presume these must be at US trial sites, correct? So, we now have 5 US sites authorized to enroll and treat patients.
Will we get an NR when Patient 1 has been enrolled/treated?
Is it possible they already enrolled and treated some patients in US without an NR?
Follow-up cystoscopy would then be at what, 90 days, 180 days, 1yr, etc... NRs for each milestone, probably a combined NR for a group of patients all treated around the same time?
Potential for Bought Deals, Joint Ventures in the next 6mos - 1yr?
Movement/Interest on the anti-Covid PDC angle or was this just bandwagoning?